Nurix Therapeutics, Inc. (NRIX) Profit Margins
Over the twelve months to 2026-08-31, Nurix Therapeutics, Inc. (NRIX) had operating margin 41.3%, net margin 42.0%, free cash flow margin 52.7%, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-08-31 · read by EquiReason
NRIXNurix Therapeutics, Inc.Follow NRIX — free
—
Price chart with a free account
- Market cap
- 2.8B
- P/E TTM
- 10.0
- Dividend yield
- 0.0%
- 52-week
- —
- Next earnings
- 26 Jan, in 94 days
| Line | FY2020 Nov 20 | FY2021 Nov 21 | FY2022 Nov 22 | FY2023 Nov 23 | FY2024 Nov 24 | FY2025 Nov 25 | TTM Aug 26 | Trend |
|---|---|---|---|---|---|---|---|---|
| Operating margin | -364.7% | -396.3% | -476.0% | -201.4% | -390.5% | -340.2% | 41.3% | |
| Net margin | -242.7% | -393.9% | -466.9% | -187.0% | -354.9% | -314.9% | 42.0% | |
| FCF margin | -26.0% | -302.6% | -445.4% | -116.6% | -333.4% | -313.7% | 52.7% |
USD billions · SEC XBRL
Nurix Therapeutics, Inc. — questions
- What is Nurix Therapeutics, Inc.'s operating margin?
- 41.3% over the twelve months to 2026-08-31.
- What is Nurix Therapeutics, Inc.'s net profit margin?
- 42.0% over the twelve months to 2026-08-31.
Every figure on this page comes from Nurix Therapeutics, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.